Seven Eight Capital’s Emergent Biosolutions EBS Stock Holding History

Seven Eight Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,200	Closed	-$658K	–	516
2019 Q4	$658K	Buy	12,200 +7,700	+171%	+$418K	0.03%	503
2019 Q3	$235K	Buy	+4,500	New	+$210K	0.01%	563
2019 Q2	–	Sell	-7,800	Closed	-$394K	–	623
2019 Q1	$394K	Sell	7,800 -3,000	-28%	-$177K	0.02%	464
2018 Q4	$640K	Buy	+10,800	New	+$696K	0.04%	401
2018 Q2	–	Sell	-13,300	Closed	-$700K	–	495
2018 Q1	$700K	Buy	+13,300	New	+$663K	0.06%	249

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Seven Eight Capital's EBS Position: Q1 2020 in Review

Seven Eight Capital sold out of Emergent Biosolutions (EBS) in Q1 2020, closing a stake of 12,200 shares — an estimated $658K sold.

Seven Eight Capital first reported a position in EBS in Q1 2018 and held it in 5 quarters. The position peaked at $700K in Q1 2018. 263 funds tracked by Wall St. Rank hold EBS as of Q1 2020.

Seven Eight Capital reported no remaining Emergent Biosolutions position as of Q1 2020 after selling out during the quarter.
Seven Eight Capital sold 12,200 Emergent Biosolutions shares in Q1 2020, an estimated $658K.
Seven Eight Capital first reported a position in Emergent Biosolutions in Q1 2018 and held it in 5 quarters.
Seven Eight Capital's Emergent Biosolutions position peaked at $700K in Q1 2018.
263 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2020.

Based on Seven Eight Capital's 13F filing for Q1 2020, filed 14 May 2020.